TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34098739
Drug: Twirla (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twirla (2.3 mg ethinyl estradiol and 2.6 mg levonorgestrel)
Study: 36352762
Drug: Tregopil 30
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregopil 30 mg
Study: 36352762
Drug: Tregopil 45
Normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregopil 45 mg
Study: 33158423
Drug: Oral neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neuromuscular training with an oral device (Muppy®) for 5 weeks
Study: 33579525
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation in cultures of normal human granulosa cells in vitro
Study: 33579525
Drug: Insulin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin concentration of 100 nmol/L for 12 hours
Study: 36201360
Drug: Ozoralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozoralizumab 30 mg
Study: 36201360
Drug: Ozoralizumab 80
Normalized name: Ozoralizumab
DrugBank: Ozoralizumab (DB12014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozoralizumab 80 mg
Study: 32759439
Drug: Pectoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoral nerve block with ropivacaine 0.375% 30 ml
Study: 32759439
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block with ropivacaine 0.5% 20 ml
Study: 33308429
Drug: Monovalent OPV2
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent OPV2 (1 or 2 doses)
Study: 33308429
Drug: Novel OPV2‐c1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel OPV2‐c1 (1 or 2 doses)
Study: 33308429
Drug: Novel OPV2‐c2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel OPV2‐c2 (1 or 2 doses)
Study: 33308429
Drug: Novel OPV2‐c1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel OPV2‐c1 (2 doses) in IPV-vaccinated participants
Study: 33308429
Drug: Novel OPV2‐c2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel OPV2‐c2 (2 doses) in IPV-vaccinated participants
Study: 33308429
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 doses) in IPV-vaccinated participants
Study: 33308429
Drug: Novel OPV2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel OPV2 candidates (1 dose)
Study: 33308429
Drug: Monovalent OPV2
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent OPV2 (1 dose)
Study: 32857106
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant
Study: 37143040
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg/day)
Study: 33037801
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg)
Study: 35441926
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group with support tool app for medication intake reminders and motivational messages
Study: 36201995
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for GAD
Study: 32831984
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous infusion of 5 mg zoledronic acid (ZOL)
Study: 36172051
Drug: Phenylephrine (0.54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.54 μg/kg/min)
Study: 36172051
Drug: Norepinephrine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (0.08 μg/kg/min)
Study: 36172051
Drug: Metaraminol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaraminol (2 μg/kg/min)
Study: 35997325
Drug: Favipiravir (FPV)
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir (FPV) 1800 mg BID on Day 1 and 800 mg BID for 5-14 days thereafter
Study: 32111892
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (PPV)
Study: 32111892
Drug: IVB injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB injections
Study: 32631958
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy (table fan)
Study: 32631958
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy
Study: 34958382
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 5 μg or 10 μg of a SARS-CoV-2 inactivated vaccine
Study: 34887772
Drug: Moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity statin therapy
Study: 34262261
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg frovatriptan succinate tablet (single-dose)
Study: 34262261
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg frovatriptan succinate tablet (single-dose)
Study: 34262261
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg frovatriptan succinate tablet (single-dose)
Study: 34262261
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg frovatriptan succinate tablet (multiple-dose, 12 times in 7 days)
Study: 34411221
Drug: DAS (implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS (implants with surface modified by double acid‐etching and sandblasting)
Study: 34411221
Drug: DAS-H (implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS-H (implants with surface modified by double acid‐etching and sandblasting, stored in 0.9% saline solution)
Study: 35381390
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) therapy
Study: 35107429
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care (EC) with continuous glucose monitoring and low-carbohydrate nutrition counseling (<100 g/day)
Study: 35699263
Drug: Therapy Program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy Program for Management of Chronic Cough (TMCC)
Study: 36397102
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review, patient counselling, and information transmission to general practitioners and community pharmacies after discharge
Study: 35986297
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day)
Study: 36074747
Drug: Copper oxide
Normalized name: Copper oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper oxide wire particles (COWP) 2 g administered orally
Study: 36074747
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control capsule
Study: 34791074
Drug: Fosfomycin (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3g once daily for 10 days)
Study: 34791074
Drug: Ciprofloxacin (0.5g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (0.5g twice daily for 10 days)
Study: 32711957
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + ICE (ice slurry ingestion)
Study: 32711957
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + AMB (ambient water ingestion)
Study: 33811761
Drug: Velusetrag 5
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velusetrag 5 mg
Study: 35265302
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) combined with conventional physical therapy
Study: 39775073
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy alone
Study: 32299355
Drug: LPS (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (10 μg/ml)
Study: 32299355
Drug: Poly (I:C)
Normalized name: C.I. acid blue 324
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly (I:C) (10 μg/ml)
Study: 32299355
Drug: Heat-inactivated Vibrio
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated Vibrio harveyi (107 cell/ml)
Study: 32299355
Drug: LPS dose-increased
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS dose-increased treatment (0, 10, 20, and 50 μg/ml)
Study: 32129194
Drug: Alpha-keto analogue
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-keto analogue (600 mg tablet three times a day)
Study: 32129194
Drug: Alpha-keto analogue
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-keto analogue (600 mg tablet three times a day) + Nigella sativa oil (2.5 mL, per orally, once daily) for 12 weeks
Study: 34755007
Drug: Monthly minodronate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly minodronate (MIN group)
Study: 33324264
Drug: Vignette 2
Normalized name: Ultra Violette Mini Mates Duo Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vignette 2 (patient receiving amlodipine treatment)
Study: 32715744
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound treatment
Study: 38580558
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOAC)
Study: 34498307
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract tablets
Study: 32674447
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone
Study: 35931103
Drug: IMGX003 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMGX003 (1200 mg)
Study: 32748473
Drug: Silymarin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (40 g/day)
Study: 35918106
Drug: Daprodustat three
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat three times weekly
Study: 33125769
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without treatment (OBS)
Study: 32114186
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment
Study: 34036760
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (I Love You method), 15 minutes before feeding, twice a day for 5 days
Study: 33549600
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information plus an information pamphlet (Group 1; n = 45)
Study: 33549600
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information alone (Group 2; n = 45)
Study: 35787693
Drug: Solutech (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutech (10.0 mg Δ9‐THC, 9.76 mg CBD)
Study: 35787693
Drug: MCT-oil (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT-oil (10.0 mg Δ9‐THC, 9.92 mg CBD)
Study: 33502237
Drug: Intense neoadjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense neoadjuvant androgen deprivation therapy followed by radical prostatectomy
Study: 33502237
Drug: Testosterone recovery
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone recovery post-treatment
Study: 33189627
Drug: Lisinopril (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (in participants with diabetes)
Study: 33189627
Drug: Lisinopril (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (in diabetes-free participants)
Study: 33462940
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment (Essentiale plus Yasmin)
Study: 32744056
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of aspirin therapy during the perioperative period (33 eyes)
Study: 32744056
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of aspirin therapy for 3 to 7 days before surgery (34 eyes)
Study: 32744056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no antiplatelet/anticoagulant therapy (43 eyes)
Study: 35109491
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GMT and RCS
Study: 36280113
Drug: Dapagliflozin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin treatment for 5 weeks
Study: 32562450
Drug: Smectite at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smectite at 0.5 g/kg PO per day divided in two to three doses
Study: 32562450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without initial medication
Study: 35834790
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nivolumab + ipilimumab)
Study: 34416347
Drug: Semi-active control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-active control treatment (electromyogram biofeedback)
Study: 34416347
Drug: SCP-NF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCP-NF and Semi-active control treatment
Study: 35708431
Drug: TAP (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP (triple antibiotic paste)
Study: 34851731
Drug: Providing children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providing children with >60 minutes of outdoor play daily
Study: 34953603
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 77 Gy to the entire prostate in 35 fractions
Study: 34099307
Drug: TAU arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAU arm (treatment-as-usual, testing results not available until 8-week visit, n = 92)
Study: 35961356
Drug: Typhoid conjugate
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid conjugate vaccine (TCV)
Study: 35961356
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup A conjugate vaccine (MCV-A)
Study: 32333539
Drug: Medication (Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Diclofenac Sodium and Mecobalamine)
Study: 35551290
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg d−1 with closed-loop therapy
Study: 35551290
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg d−1 with sensor-augmented pump (SAP) therapy
Study: 35551290
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy plus empagliflozin
Study: 35551290
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with closed-loop therapy
Study: 35551290
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with SAP therapy
Study: 33914770
Drug: Trusting peer
Normalized name: Polar Frost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trusting peer educators for HIV treatment
Study: 36027483
Drug: Vinorelbine/Cisplatin (Chemotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine/Cisplatin (Chemotherapy)
Study: 33105928
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate capsules with sofosbuvir tablets
Study: 33105928
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate capsules with omeprazole magnesium enteric-coated tablets
Study: 33105928
Drug: Yimitasvir phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir phosphate capsules with rosuvastatin calcium tablets
Study: 35294067
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) defined by HOMA-IR >2.5
Study: 35294067
Drug: Non-insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin resistance (non-IR)
Study: 32557001
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser therapy with 50 units of BTX-A solution applied topically post-operatively
Study: 86263812
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acids (0.25 g/kg/day)
Study: 86263812
Drug: Casein (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (0.25 g/kg/day)
Study: 32317241
Drug: Machine learning-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machine learning-based treatment planning system (PIPA system)
Study: 32317241
Drug: Conventional, manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, manual treatment planning technique
Study: 35474582
Drug: Sublingual 300
Normalized name: Oralair 300 Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 300 IR HDM tablets
Study: 36033243
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin anticoagulation for CRRT
Study: 36134707
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model developed using clinical and drug-related variables from training data set.
Study: 32519599
Drug: Regular low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular low-dose sustained-release morphine (8-32 mg/24 h)
Study: 35275529
Drug: DHP1401 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP1401 500 mg
Study: 35275529
Drug: DHP1401 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP1401 1000 mg
Study: 35275529
Drug: DHP1401 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP1401 500 mg and Donepezil 5 mg
Study: 33567928
Drug: Antiviral drug
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drug (oseltamivir) alone
Study: 32107956
Drug: Serum miR‐125b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum miR‐125b in combination with serum CA125
Study: 36253766
Drug: Tele-delivered problem-solving
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-delivered problem-solving therapy (Tele-PST)
Study: 33449527
Drug: Cellex (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellex (0.1 mg daily SC for 10 days)
Study: 33449527
Drug: Cortexin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin (10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days)
Study: 33587381
Drug: DaxibotulinumtoxinA for
Normalized name: daxibotulinumtoxinA-lanm
Approvals — FDA: no, EMA: no, PMDA: no
Description: DaxibotulinumtoxinA for Injection (DAXI)
Study: 33029812
Drug: PDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS with calcium concentration of 1.75 mmol/L (high concentration group)
Study: 33029812
Drug: PDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS with calcium concentration of 1.25 mmol/L (low concentration group)
Study: 32928500
Drug: Antipsychotic-naïve patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-naïve patients
Study: 39326506
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT)
Study: 33735217
Drug: Less invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less invasive treatments
Study: 33084149
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg and 25 mg
Study: 35471469
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day tolvaptan (TLV) plus original FUR dose for 7 days
Study: 35471469
Drug: 120–200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120–200 mg/day furosemide (FUR) for 7 days
Study: 34187185
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg once daily for 26 weeks)
Study: 34187185
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 26 weeks)
Study: 34148643
Drug: Multimodal protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal protocol combining a motivational interview, subcutaneous injection of NicoSan®, and hyperhydration.
Study: 35590388
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical diclofenac gel
Study: 34480575
Drug: SCB-2019 vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 vaccine (3, 9, or 30 µg doses)
Study: 35742477
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (information related to daily recommended PA levels)
Study: 36478528
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 12 μg
Study: 36478528
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 18 μg